Rheumatoid and pyrophosphate arthritis synovial fibroblasts induce osteoclastogenesis independently of RANKL, TNF and IL-6

Journal of Autoimmunity

Volumn 39, Issue 4, 2012, Pages 369-376

  Dickerson, Tiffany J ^a   Suzuki, Erika ^a   Stanecki, Catherine ^b   Shin, Hyun Seock ^a   Qui, Hong ^a   Adamopoulos, Iannis E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

Author keywords

Arthritis; Osteoclast; RANKL; Rheumatoid arthritis; Synovial fibroblast

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; COLONY STIMULATING FACTOR 1; F ACTIN; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PYROPHOSPHATE; TUMOR NECROSIS FACTOR; VITRONECTIN RECEPTOR;

ADULT; AGED; ARTHROPATHY; ARTICLE; BONE DESTRUCTION; CLINICAL ARTICLE; CONTROLLED STUDY; FIBROBLAST; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; OSTEOARTHRITIS; OSTEOCLASTOGENESIS; OSTEOLYSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SYNOVIUM;

ACID PHOSPHATASE; ACTINS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; CHONDROCALCINOSIS; CULTURE MEDIA, CONDITIONED; FIBROBLASTS; GENE EXPRESSION REGULATION; HUMANS; INTEGRIN ALPHAVBETA3; INTERLEUKIN-6; ISOENZYMES; LEUKOCYTES, MONONUCLEAR; OSTEOARTHRITIS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84869881878     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2012.06.001     Document Type: Article

References (51)

1. Aidinis V., Plows D., Haralambous S., Armaka M., Papadopoulos P., Kanaki M.Z., et al. Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res Ther 2003, 5:R140-R157.
2. Edwards J.C. Fibroblast biology. Development and differentiation of synovial fibroblasts in arthritis. Arthritis Res 2000, 2:344-347.
3. Muller-Ladner U., Gay R.E., Gay S. Activation of synoviocytes. Curr Opin Rheumatol 2000, 12:186-194.
4. Pap T., Muller-Ladner U., Gay R.E., Gay S. Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res 2000, 2:361-367.
5. Kontoyiannis D., Kollias G. Fibroblast biology. Synovial fibroblasts in rheumatoid arthritis: leading role or chorus line?. Arthritis Res 2000, 2:342-343.
6. Lehmann J., Jungel A., Lehmann I., Busse F., Biskop M., Saalbach A., et al. Grafting of fibroblasts isolated from the synovial membrane of rheumatoid arthritis (RA) patients induces chronic arthritis in SCID mice-A novel model for studying the arthritogenic role of RA fibroblasts in vivo. J Autoimmun 2000, 15:301-313.
7. Hata H., Sakaguchi N., Yoshitomi H., Iwakura Y., Sekikawa K., Azuma Y., et al. Distinct contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice. J Clin Invest 2004, 114:582-588.
8. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
9. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G.D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J Immunol 1990, 144:4226-4230.
10. Athanasou N.A. Cellular biology of bone-resorbing cells. J Bone Joint Surg Am 1996, 78:1096-1112.
11. Alexander G.M., Dieppe P.A., Doherty M., Scott D.G. Pyrophosphate arthropathy: a study of metabolic associations and laboratory data. Ann Rheum Dis 1982, 41:377-381.
12. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
13. Quinn J.M., Elliott J., Gillespie M.T., Martin T.J. A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 1998, 139:4424-4427.
14. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982, 34:285-290.
15. Blair H.C., Teitelbaum S.L., Ghiselli R., Gluck S. Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 1989, 245:855-857.
16. Gravallese E.M., Manning C., Tsay A., Naito A., Pan C., Amento E., et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000, 43:250-258.
17. Takayanagi H., Iizuka H., Juji T., Nakagawa T., Yamamoto A., Miyazaki T., et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000, 43:259-269.
18. Haynes D.R., Crotti T.N., Loric M., Bain G.I., Atkins G.J., Findlay D.M. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001, 40:623-630.
19. Pilichou A., Papassotiriou I., Michalakakou K., Fessatou S., Fandridis E., Papachristou G., et al. High levels of synovial fluid osteoprotegerin (OPG) and increased serum ratio of receptor activator of nuclear factor-kappa B ligand (RANKL) to OPG correlate with disease severity in patients with primary knee osteoarthritis. Clin Biochem 2008, 41:746-749.
20. Wakita T., Mogi M., Kurita K., Kuzushima M., Togari A. Increase in RANKL: OPG ratio in synovia of patients with temporomandibular joint disorder. J Dent Res 2006, 85:627-632.
21. Kudo O., Sabokbar A., Pocock A., Itonaga I., Fujikawa Y., Athanasou N.A. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003, 32:1-7.
22. Kudo O., Fujikawa Y., Itonaga I., Sabokbar A., Torisu T., Athanasou N.A. Proinflammatory cytokine (TNFalpha/IL-1alpha) induction of human osteoclast formation. J Pathol 2002, 198:220-227.
23. Adamopoulos I., Sabokbar A., Wordsworth B., Carr A., Ferguson D., Athanasou N. Synovial fluid macrophages are capable of osteoclast formation and resorption. J Pathol 2006, 208:35-43.
24. Danks L., Sabokbar A., Gundle R., Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann Rheum Dis 2002, 61:916-921.
25. Jilka R.L., Hangoc G., Girasole G., Passeri G., Williams D.C., Abrams J.S., et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992, 257:88-91.
26. Yanni G., Whelan A., Feighery C., Bresnihan B. Synovial tissue macrophages and joint erosion in rheumatoid arthritis. Ann Rheum Dis 1994, 53:39-44.
27. Takayanagi H., Oda H., Yamamoto S., Kawaguchi H., Tanaka S., Nishikawa T., et al. A new mechanism of bone destruction in rheumatoid arthritis: synovial fibroblasts induce osteoclastogenesis. Biochem Biophys Res Commun 1997, 240:279-286.
28. Athanasou N.A., Quinn J. Immunophenotypic differences between osteoclasts and macrophage polykaryons: immunohistological distinction and implications for osteoclast ontogeny and function. J Clin Pathol 1990, 43:997-1003.
29. Davies J., Warwick J., Totty N., Philp R., Helfrich M., Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 1989, 109:1817-1826.
30. Pfeilschifter J., Chenu C., Bird A., Mundy G.R., Roodman G.D. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res 1989, 4:113-118.
31. Rivollier A., Mazzorana M., Tebib J., Piperno M., Aitsiselmi T., Rabourdin-Combe C., et al. Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. Blood 2004, 104:4029-4037.
32. Lubberts E., Joosten L.A.B., Oppers B., van den Bersselaar L., Coenen-de Roo C.J.J., Kolls J.K., et al. IL-1-Independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
33. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999, 103:1345-1352.
34. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
35. Chambers T.J. Regulation of the differentiation and function of osteoclasts. J Pathol 2000, 192:4-13.
36. Jaffre F., Callebert J., Sarre A., Etienne N., Nebigil C.G., Launay J.-M., et al. Involvement of the Serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation. Circulation 2004, 110:969-974.
37. Werth V.P., Bashir M.M., Zhang W. IL-12 completely blocks ultraviolet-induced secretion of tumor necrosis factor [alpha] from cultured skin fibroblasts and Keratinocytes. J Invest Dermatol 2003, 120:116-122.
38. Kubota A., Hasegawa K., Suguro T., Koshihara Y. Tumor necrosis factor-alpha promotes the expression of osteoprotegerin in rheumatoid synovial fibroblasts. J Rheumatol 2004, 31:426-435.
39. Guba S.C., Sartor C.I., Gottschalk L.R., Jing Y.H., Mulligan T., Emerson S.G. Bone marrow stromal fibroblasts secrete interleukin-6 and granulocyte-macrophage colony-stimulating factor in the absence of inflammatory stimulation: demonstration by serum-free bioassay, enzyme-linked immunosorbent assay, and reverse transcriptase polymerase chain reaction. Blood 1992, 80:1190-1198.
40. Hodge J.M., Kirkland M.A., Nicholson G.C. GM-CSF cannot substitute for M-CSF in human osteoclastogenesis. Biochem Biophys Res Commun 2004, 321:7-12.
41. Hodge J.M., Kirkland M.A., Aitken C.J., Waugh C.M., Myers D.E., Lopez C.M., et al. Osteoclastic potential of human CFU-GM: biphasic effect of GM-CSF. J Bone Miner Res 2004, 19:190-199.
42. Hiasa M., Abe M., Nakano A., Oda A., Amou H., Kido S., et al. GM-CSF and IL-4 induce dendritic cell differentiation and disrupt osteoclastogenesis through M-CSF receptor shedding by up-regulation of TNF-alpha converting enzyme (TACE). Blood 2009, 114:4517-4526.
43. Schiller C., Gruber R., Ho G.M., Redlich K., Gober H.J., Katzgraber F., et al. Interaction of triiodothyronine with 1alpha,25-dihydroxyvitamin D3 on interleukin-6-dependent osteoclast-like cell formation in mouse bone marrow cell cultures. Bone 1998, 22:341-346.
44. Gao Y., Morita I., Maruo N., Kubota T., Murota S., Aso T. Expression of IL-6 receptor and GP130 in mouse bone marrow cells during osteoclast differentiation. Bone 1998, 22:487-493.
45. Peters M., Muller A.M., Rose-John S. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood 1998, 92:3495-3504.
46. Benigni F., Fantuzzi G., Sacco S., Sironi M., Pozzi P., Dinarello C.A., et al. Six different cytokines that share GP130 as a receptor subunit, induce serum amyloid A and potentiate the induction of interleukin-6 and the activation of the hypothalamus-pituitary-adrenal axis by interleukin-1. Blood 1996, 87:1851-1854.
47. Astry B., Harberts E., Moudgil K.D. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011, 31:927-940.
48. Murakami M., Hibi M., Nakagawa N., Nakagawa T., Yasukawa K., Yamanishi K., et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993, 260:1808-1810.
49. Yawata H., Yasukawa K., Natsuka S., Murakami M., Yamasaki K., Hibi M., et al. Structure-function analysis of human IL-6 receptor: dissociation of amino acid residues required for IL-6-binding and for IL-6 signal transduction through gp130. EMBO J 1993, 12:1705-1712.
50. Adamopoulos I.E., Tessmer M., Chao C.C., Adda S., Gorman D., Petro M., et al. IL-23 is critical for induction of arthritis, osteoclast formation, and maintenance of bone mass. J Immunol 2011, 187:951-959.
51. Hsu Y.H., Chen W.Y., Chan C.H., Wu C.H., Sun Z.J., Chang M.S. Anti-IL-20 monoclonal antibody inhibits the differentiation of osteoclasts and protects against osteoporotic bone loss. J Exp Med 2011, 208:1849-1861.